Pharmaeconomica BV

Pharmaeconomica BV

Biotechnology Research

Ostend, Flemish Region 258 followers

Insights beyond the usual

About us

Pharmaeconomica, headquartered in Belgium, pioneers AI-driven small-molecule drug discovery. Our innovative approach integrates cutting-edge AI technology, revolutionizing traditional processes to accelerate steps, enhance efficiency, and slash costs associated with experiments. By minimizing the need for physical experiments, our AI-driven platform optimizes discovery tasks like molecule design and testing, ensuring effective validation of results. Innovating Drug Discovery with Pharmaeconomica At Pharmaeconomica, we're at the forefront of drug discovery innovation. With a seasoned team, we prioritize solutions for therapeutic areas with high unmet medical needs, driving groundbreaking advancements in the field. Revolutionary ML Platform for Identifying AD Inhibitors Powered by machine learning, our proprietary platform swiftly analyzes extensive datasets, uncovering novel drug candidates with unrivaled efficiency. Focused on Alzheimer's disease, we're committed to identifying inhibitors that target its complex nature, aiming to enhance patient outcomes significantly. Empirical Evidence and Theoretical Models Supporting Our Platform Our platform shows promising results, surpassing traditional methods in identifying potential AD inhibitors. Computational models forecast substantial reductions in key markers of Alzheimer's progression, underlining our platform's potential impact. Beyond Alzheimer's: A Versatile Platform for Drug Discovery While Alzheimer's remains our initial focus, our adaptable platform enables swift adaptation to other disease targets. Continuously enhancing our capabilities, we actively seek partnerships to propel the future of personalized medicine.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Ostend, Flemish Region
Type
Privately Held
Founded
2023
Specialties
HEOR, Health economic evaluations, Market Access, Value Communication, Evidence synthesis, Network meta-analysis, Indirect treatment comparison, Systematic Literature Reviews, Pricing, Infectious disease modeling, Mathematical modeling, Statistical modeling, Early value assessment, Medtech, Biotech, Insilico Drug Discovery, AI-driven drug discovey, AI-driven drug discovery platform, Peptide extension approach, and Machine Learning

Locations

Employees at Pharmaeconomica BV

Updates

  • Pharmaeconomica BV reposted this

    View profile for Jorge Emilio Alfonso, graphic

    Founder and Managing Director at PHARMAECONOMICA BV

    Achieving Product Launch Success Through Essential Market Insights. (Part I) In today’s competitive landscape, a successful launch strategy is more than just preparation—it’s about actively shaping the market. At Pharmaeconomica, we help you building a comprehensive strategy by addressing key questions that ensure your Market Access efforts are as impactful as possible: - Is your strategy grounded in a deep market understanding? We provide insights into the treatment landscape, including standard pathways and KOL connections, and engage decision-makers to influence standards and guidelines. - Is your strategy built on clear patient insights? Our approach dives into patient demographics, payer coverage by lives and revenue, and identifies patient subgroups for maximum payer value. - Is your strategy informed by payer insights? We deliver knowledge of payer structures, formulary decisions, and unmet needs across cost and outcomes, ensuring effective payer engagement. - Is your strategy aligned with health system insights? By understanding institutions like GBA in Germany or NICE in the UK, we create market access strategies aligned with each local health system. - Is your strategy backed by health economics insights? We leverage health economics data, customer value drivers, and adaptable models for productive payer discussions. With Pharmaeconomica, ensure your launch strategy doesn’t just enter the market—it shapes it. Connect with us today to set your product launch up for excellence. #ProductLaunch, #MarketAccess, #HealthEconomics, #PatientInsights, #PayerStrategy, #Pharmaeconomica, #KOLengagement, #MarketStrategy #LaunchExcellence

    • No alternative text description for this image
  • Pharmaeconomica BV reposted this

    View profile for Jorge Emilio Alfonso, graphic

    Founder and Managing Director at PHARMAECONOMICA BV

    Is Your Product Launch Set for Success—or at Risk? Pharmaeconomica’s Launch Maturity Tool is your solution for a flawless launch. In a competitive landscape, missing even one step can mean lost market share, delayed revenue, and missed connections with stakeholders. Our tool pinpoints readiness across seven essential areas—pricing, market access, stakeholder engagement, and more—to ensure every aspect of your launch is optimized. Don't leave your product's success to chance. Take control of your launch’s success. Connect with us today to see how Pharmaeconomica can make your launch strategy unstoppable.

    • No alternative text description for this image
  • Pharmaeconomica BV reposted this

    View profile for Jorge Emilio Alfonso, graphic

    Founder and Managing Director at PHARMAECONOMICA BV

    We are happy to present our latest white paper, "Beyond Needlesticks: Multi-Chamber Bags Enhanced with Smart Injection and Infusion Technology," created through a collaboration between B. Braun and Pharmaeconomica. This publication explores innovative solutions in parenteral nutrition, focusing on multi-chamber bag (MCB) designs that enhance safety and help reduce needlestick injuries for healthcare professionals. Our partnership is dedicated to setting new standards in healthcare safety and efficiency. https://lnkd.in/e5E-ka8W

    • No alternative text description for this image
  • View organization page for Pharmaeconomica BV, graphic

    258 followers

    Exciting times at Pharmaeconomica as we explore innovative solutions for combating obesity! Our focus on the PrRP-GPR10 signaling pathway is uncovering new strategies to restore energy balance and metabolic health. Disruptions in this pathway are linked to obesity, impaired glucose regulation, and increased fat storage. By targeting GPR10, we aim to address these challenges head-on, offering a novel approach to obesity treatment that enhances satiety and boosts thermogenesis. We’re excited to share our latest blog post on ThinkML. In this article, we dive into the innovative approaches that Pharmaeconomica BV is using to tackle obesity, one of the most pressing health challenges of our time. From cutting-edge computational strategies to novel treatment methodologies, we explore how we're pushing the boundaries of science to develop more effective solutions. If you're interested in the future of obesity treatment, this is a must-read! Check out the full article at https://lnkd.in/dgRJqicc hashtag #ObesityTreatment hashtag #Pharmaeconomica hashtag #ThinkML hashtag #Healthcare #Pharmaeconomica #ObesityResearch #MetabolicHealth #InnovationInHealthcare

    • No alternative text description for this image
  • Pharmaeconomica BV reposted this

    View profile for Kanzal Iman, PhD, graphic

    Co-Founder and Director at Pharmaeconomica

    Pharmaeconomica BV is thrilled to share progress on our groundbreaking project - Peptide Engineering for Obesity. Our goal is to design selective agonists for GPR10, a promising approach to treating obesity by targeting energy balance and appetite regulation. What sets our work apart? We’ve integrated cutting-edge AI-based homology modeling with traditional techniques that has allowed us to achieve unprecedented accuracy and reliability in modeling GPR10. This innovative integration of AI and advanced computational methods ensures that our research is at the forefront of science alongside paving the way for novel therapeutic approaches. We’re excited about the potential impact of our work and are confident that our unique approach will lead to significant breakthroughs in obesity treatment. To collaborate with us or to learn more about our work, please reach out to us at www.pharmaeconomica.com Follow Pharmaeconomica BV and stay tuned for more updates as we continue to push the boundaries of what’s possible in this critical area of research! #ObesityResearch #AIinHealthcare #PeptideEngineering #GPCR #Innovation #Pharmaeconomica

    Pharmaeconomica | AI-Driven Drug Discovery

    Pharmaeconomica | AI-Driven Drug Discovery

    pharmaeconomica.com

  • Pharmaeconomica BV reposted this

    View profile for Kanzal Iman, PhD, graphic

    Co-Founder and Director at Pharmaeconomica

    Pharmaeconomica BV is actively seeking collaborations to advance our cutting-edge work in drug discovery. Our team of experts is utilizing advanced AI and state-of-the-art computational chemistry to drive multiple promising projects. Here’s what we bring to the table: 1. Designing selective agonists and antagonists targeting novel receptors to address significant health challenges. 2. Exploiting sophisticated AI algorithms for the rapid identification and optimization of therapeutic candidates. 3. Utilizing cutting-edge computational approaches to enhance precision and efficacy in drug development. 4. A team of computational chemists and data scientists dedicated to transformative research. Our innovative approach has already led to a patent pending for a groundbreaking BuChE inhibitor, highlighting our platform's potential in addressing neurodegenerative disorders. Our ongoing projects showcase our capability and ambition to revolutionize the pharmaceutical landscape. We believe in the power of collaboration to unlock new therapeutic possibilities. Interested in partnering with us? Let’s explore potential opportunities to work together on transformative therapies. Learn more at https://lnkd.in/dPx7prkU #DrugDiscovery #Collaboration #PeptideEngineering #AIinPharma #Healthcare #CADD

    Pharmaeconomica | AI-Driven Drug Discovery

    Pharmaeconomica | AI-Driven Drug Discovery

    pharmaeconomica.com

  • View organization page for Pharmaeconomica BV, graphic

    258 followers

    Pharmaeconomica is targeting GPR10 as a potential target for weight-loss therapy — a promising alternative to the crowded GLP-1.

    View profile for Kanzal Iman, PhD, graphic

    Co-Founder and Director at Pharmaeconomica

    Pharmaeconomica BV is excited to share our latest advancements in peptide engineering, where we are targeting a novel receptor to tackle a significant health challenge. By integrating advanced AI algorithms with state-of-the-art computational chemistry, our team of experts is designing selective agonists with promising potential. Stay tuned as we continue to drive innovation and pursue our mission to discover and develop transformative therapies. Interested in collaborating or learning more? Connect with Pharmaeconomica BV to explore potential opportunities. #DrugDiscovery #PeptideEngineering #Pharmaeconomica #AIinPharma #BiotechInnovation #Healthcare

  • View organization page for Pharmaeconomica BV, graphic

    258 followers

    Pharmaeconomica's AI-driven PREDIT platform is revolutionizing drug discovery. By leveraging computational chemistry and machine learning, we've accelerated the identification of therapeutic leads, including potent, brain-specific and selective BuChE inhibitors for Alzheimer's and other neurodegenerative diseases. Discover how PREDIT is transforming drug discovery, reducing timelines, and uncovering new therapeutic opportunities in this article: https://lnkd.in/eh8zXMf7

    PREDIT: AI Success Story in Drug Discovery

    PREDIT: AI Success Story in Drug Discovery

    thinkml.ai

  • View organization page for Pharmaeconomica BV, graphic

    258 followers

    At Pharmaeconomica BV, we recognize the critical role of G protein-coupled receptors (GPCRs) in drug discovery. With nearly 800 members, GPCRs regulate essential functions like blood pressure and the hormone system, making them prime targets for treating diseases such as diabetes and obesity. Despite the growing number of published GPCR structures, molecular modeling tools like Rosetta are vital to bridging knowledge gaps. We leverage advanced modeling protocols to generate high-quality homology models, driving innovation in the development of targeted therapies. Join us in our mission to revolutionize healthcare through cutting-edge science and technology! #DrugDiscovery #GPCR #Biotech #Pharmaeconomica #HealthcareInnovation #Homologymodel

    • No alternative text description for this image
  • View organization page for Pharmaeconomica BV, graphic

    258 followers

    We’ve updated our website! Discover our state-of-the-art AI-driven drug discovery platform, explore our innovative pipeline projects targeting neurodegenerative diseases, obesity, and antiviral treatments, and learn about our comprehensive consulting services. At Pharmaeconomica, we are dedicated to accelerating drug discovery and development with cutting-edge technology and expertise. Visit us today and see how we are transforming the pharmaceutical landscape. Check it out at www.pharmaeconomica.com #Pharmaeconomica #DrugDiscovery #AI #ComputationalChemistry #Biotech #Pharmaceuticals #Innovation #Healthcare #Science #Research #Consulting #HealthcareInnovation #Biotechnology #PharmaTech #InvestInInnovation #FutureOfMedicine #LifeSciences #TherapeuticDevelopment

    Pharmaeconomica | AI-Driven Drug Discovery

    Pharmaeconomica | AI-Driven Drug Discovery

    pharmaeconomica.com

Similar pages